Factors associated with beta-cell dysfunction in type 2 diabetes: The BETADECLINE study

Giuseppina T. Russo; Carlo Bruno Giorda; Stefania Cercone; Antonio Nicolucci; Domenico Cucinotta; S. Leotta; A. Arcangeli; M. Calabrese; G. Vespasiani; S. De Cosmo; A. Corda; L. Gentile; M. A. Pellegrini

doi:10.1371/journal.pone.0109702

Factors associated with beta-cell dysfunction in type 2 diabetes: The BETADECLINE study

Giuseppina T. Russo, Carlo Bruno Giorda, Stefania Cercone, Antonio Nicolucci, Domenico Cucinotta, S. Leotta, A. Arcangeli, M. Calabrese, G. Vespasiani, S. De Cosmo, A. Corda, L. Gentile, M. A. Pellegrini

IRCCS Casa Sollievo della Sofferenza

Research output: Contribution to journal › Article › peer-review

Abstract

Aims: Beta-cell dysfunction is an early event in the natural history of type 2 diabetes. However, its progression is variable and potentially influenced by several clinical factors. We report the baseline data of the BetaDecline study, an Italian prospective multicenter study on clinical predictors of beta-cell dysfunction in type 2 diabetes.

Materials and Methods: Clinical, lifestyle, and laboratory data, including circulating levels of inflammatory markers and non-esterified fatty acids, were collected in 507 type 2 diabetic outpatients on stable treatment with oral hypoglycemic drugs or diet for more than 1 year. Beta-cell dysfunction was evaluated by calculating the proinsulin/insulin ratio (P/I).

Results: At baseline, the subjects in the upper PI/I ratio quartile were more likely to be men and receiving secretagogue drugs; they also showed a borderline longer diabetes duration (P=0.06) and higher serum levels of glycated hemoglobin (HbA_1c), fasting blood glucose, and triglycerides. An inverse trend across all PI/I quartiles was noted for BMI and serum levels of total cholesterol (T-C), LDL-C, HDL-C and C reactive protein (CRP), and with homeostatic model assessment (HOMA-B) and HOMA of insulin resistance (HOMA-IR) values (P

Conclusions: In the BetaDecline study population, baseline higher PI/I values, a marker of beta-cell dysfunction, were more frequent in men and in patients on secretagogues drugs. Follow-up of this cohort will allow the identification of clinical predictors of beta-cell failure in type 2 diabetic outpatients.

Original language	English
Article number	e109702
Journal	PLoS One
Volume	9
Issue number	10
DOIs	https://doi.org/10.1371/journal.pone.0109702
Publication status	Published - Oct 27 2014

ASJC Scopus subject areas

Agricultural and Biological Sciences(all)
Biochemistry, Genetics and Molecular Biology(all)
Medicine(all)

Access to Document

10.1371/journal.pone.0109702

Fingerprint Dive into the research topics of 'Factors associated with beta-cell dysfunction in type 2 diabetes: The BETADECLINE study'. Together they form a unique fingerprint.

Cite this

Factors associated with beta-cell dysfunction in type 2 diabetes : The BETADECLINE study. / Russo, Giuseppina T.; Giorda, Carlo Bruno; Cercone, Stefania; Nicolucci, Antonio; Cucinotta, Domenico; Leotta, S.; Arcangeli, A.; Calabrese, M.; Vespasiani, G.; De Cosmo, S.; Corda, A.; Gentile, L.; Pellegrini, M. A.

In: PLoS One, Vol. 9, No. 10, e109702, 27.10.2014.

Research output: Contribution to journal › Article › peer-review

@article{27a719aa9c3c4fe3824a85d779baba1a,

title = "Factors associated with beta-cell dysfunction in type 2 diabetes: The BETADECLINE study",

abstract = "Aims: Beta-cell dysfunction is an early event in the natural history of type 2 diabetes. However, its progression is variable and potentially influenced by several clinical factors. We report the baseline data of the BetaDecline study, an Italian prospective multicenter study on clinical predictors of beta-cell dysfunction in type 2 diabetes.Materials and Methods: Clinical, lifestyle, and laboratory data, including circulating levels of inflammatory markers and non-esterified fatty acids, were collected in 507 type 2 diabetic outpatients on stable treatment with oral hypoglycemic drugs or diet for more than 1 year. Beta-cell dysfunction was evaluated by calculating the proinsulin/insulin ratio (P/I).Results: At baseline, the subjects in the upper PI/I ratio quartile were more likely to be men and receiving secretagogue drugs; they also showed a borderline longer diabetes duration (P=0.06) and higher serum levels of glycated hemoglobin (HbA1c), fasting blood glucose, and triglycerides. An inverse trend across all PI/I quartiles was noted for BMI and serum levels of total cholesterol (T-C), LDL-C, HDL-C and C reactive protein (CRP), and with homeostatic model assessment (HOMA-B) and HOMA of insulin resistance (HOMA-IR) values (PConclusions: In the BetaDecline study population, baseline higher PI/I values, a marker of beta-cell dysfunction, were more frequent in men and in patients on secretagogues drugs. Follow-up of this cohort will allow the identification of clinical predictors of beta-cell failure in type 2 diabetic outpatients.",

author = "Russo, {Giuseppina T.} and Giorda, {Carlo Bruno} and Stefania Cercone and Antonio Nicolucci and Domenico Cucinotta and S. Leotta and A. Arcangeli and M. Calabrese and G. Vespasiani and {De Cosmo}, S. and A. Corda and L. Gentile and Pellegrini, {M. A.}",

year = "2014",

month = oct,

day = "27",

doi = "10.1371/journal.pone.0109702",

language = "English",

volume = "9",

journal = "PLoS One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "10",

}

TY - JOUR

T1 - Factors associated with beta-cell dysfunction in type 2 diabetes

T2 - The BETADECLINE study

AU - Russo, Giuseppina T.

AU - Giorda, Carlo Bruno

AU - Cercone, Stefania

AU - Nicolucci, Antonio

AU - Cucinotta, Domenico

AU - Leotta, S.

AU - Arcangeli, A.

AU - Calabrese, M.

AU - Vespasiani, G.

AU - De Cosmo, S.

AU - Corda, A.

AU - Gentile, L.

AU - Pellegrini, M. A.

PY - 2014/10/27

Y1 - 2014/10/27

N2 - Aims: Beta-cell dysfunction is an early event in the natural history of type 2 diabetes. However, its progression is variable and potentially influenced by several clinical factors. We report the baseline data of the BetaDecline study, an Italian prospective multicenter study on clinical predictors of beta-cell dysfunction in type 2 diabetes.Materials and Methods: Clinical, lifestyle, and laboratory data, including circulating levels of inflammatory markers and non-esterified fatty acids, were collected in 507 type 2 diabetic outpatients on stable treatment with oral hypoglycemic drugs or diet for more than 1 year. Beta-cell dysfunction was evaluated by calculating the proinsulin/insulin ratio (P/I).Results: At baseline, the subjects in the upper PI/I ratio quartile were more likely to be men and receiving secretagogue drugs; they also showed a borderline longer diabetes duration (P=0.06) and higher serum levels of glycated hemoglobin (HbA1c), fasting blood glucose, and triglycerides. An inverse trend across all PI/I quartiles was noted for BMI and serum levels of total cholesterol (T-C), LDL-C, HDL-C and C reactive protein (CRP), and with homeostatic model assessment (HOMA-B) and HOMA of insulin resistance (HOMA-IR) values (PConclusions: In the BetaDecline study population, baseline higher PI/I values, a marker of beta-cell dysfunction, were more frequent in men and in patients on secretagogues drugs. Follow-up of this cohort will allow the identification of clinical predictors of beta-cell failure in type 2 diabetic outpatients.

AB - Aims: Beta-cell dysfunction is an early event in the natural history of type 2 diabetes. However, its progression is variable and potentially influenced by several clinical factors. We report the baseline data of the BetaDecline study, an Italian prospective multicenter study on clinical predictors of beta-cell dysfunction in type 2 diabetes.Materials and Methods: Clinical, lifestyle, and laboratory data, including circulating levels of inflammatory markers and non-esterified fatty acids, were collected in 507 type 2 diabetic outpatients on stable treatment with oral hypoglycemic drugs or diet for more than 1 year. Beta-cell dysfunction was evaluated by calculating the proinsulin/insulin ratio (P/I).Results: At baseline, the subjects in the upper PI/I ratio quartile were more likely to be men and receiving secretagogue drugs; they also showed a borderline longer diabetes duration (P=0.06) and higher serum levels of glycated hemoglobin (HbA1c), fasting blood glucose, and triglycerides. An inverse trend across all PI/I quartiles was noted for BMI and serum levels of total cholesterol (T-C), LDL-C, HDL-C and C reactive protein (CRP), and with homeostatic model assessment (HOMA-B) and HOMA of insulin resistance (HOMA-IR) values (PConclusions: In the BetaDecline study population, baseline higher PI/I values, a marker of beta-cell dysfunction, were more frequent in men and in patients on secretagogues drugs. Follow-up of this cohort will allow the identification of clinical predictors of beta-cell failure in type 2 diabetic outpatients.

UR - http://www.scopus.com/inward/record.url?scp=84908565962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908565962&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0109702

DO - 10.1371/journal.pone.0109702

M3 - Article

C2 - 25347846

AN - SCOPUS:84908565962

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e109702

ER -